Upadacitinib and certolizumab demonstrated greater efficacy in reducing signs of enthesitis in psoriatic arthritis (PsA) ...

Guselkumab, administered every 4 or 8 weeks, is effective and safe in patients with active psoriatic arthritis who have had an inadequate response to only one prior TNF inhibitor.

Learn how to manage psoriatic arthritis and psoriasis simultaneously with the right medication and treatment plan. Discover ...

Understanding the type of arthritis, its causes, and management options is the first step toward living well with the ...

Higher Mortality Risk Seen in axSpA, PsA in Real-World Study Patients with axial spondyloarthritis and psoriatic arthritis face an elevated risk for all-cause mortality compared with the general ...

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

If the sBLA is approved, expansion into psoriatic arthritis would build on the established clinical experience of ILUMYA as an IL-23 inhibitor for moderate-to-severe ...

Symptom control throughout three years: 86.1% of people living with moderate-to-severe hidradenitis suppurativa (HS) treated with BIMZELX had no acute ...

Post hoc analyses of BIMZELX (bimekizumab-bkzx) using the first consensus definition of psoriasis on-treatment remission:Published by the National ...

Alumis Inc. upgraded to Buy on strong Phase 3 psoriasis data for envudeucitinib, NDA plans, and upside valuation. Click here ...